전체 논문 (177편 · 1/6)
-
Targeting MLCK1 uncouples immune checkpoint inhibitor-induced colitis from antitumour immunity.
-
Alleviated T cell exhaustion and SLC1A3-mediated stroma-remodelling dictate chemoimmunotherapy efficacy in oesophageal squamous cell carcinoma.
-
Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition.
-
KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy.
-
Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics.
-
LY6D identifies persistent stem-like cells driving pancreatic tumourigenesis.
-
GSK3β/NFATc1 subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair.
-
NSUN6 deficiency drives immune suppression in pancreatic cancer via the KDM5A-CCL2-macrophage axis.
-
Exploiting a purine imbalance to target mutant pancreatic adenocarcinomas.
-
KRAS-driven protein disulfide isomerase family A member 6 expression suppresses PRKR-like endoplasmic reticulum kinase-mediated immunogenic cell death to desensitise pancreatic ductal adenocarcinoma to immune checkpoint blockers.
-
Trogocytosis-orchestrated CLDN18.2-"dressed" CD8 T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade.
-
MTFP1 drives pancreatic cancer liver metastatic colonisation by regulating mitochondrial metabolism reprogramming.
-
SLC6A14-mediated carnitine transmembrane uptake from PPARγ cancer-associated fibroblasts promotes recurrence of pancreatic cancer.
-
Early metabolic fate commitment in pancreatic neoplastic precursors.
-
Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer.
-
From IPMN to invasive pancreatic cancer: new spatial insights.
-
CAV1-DOT1L axis in TAM-derived EVs orchestrates VM and sensitises PDAC to combined VM and VEGF targeting.
-
Hereditary chronic pancreatitis induced plasticity cooperates with mutant Kras in early pancreatic carcinogenesis.
-
-derived methionine promotes gastric cancer progression.
-
Gastric cancer attributable to in 2040.
-
Prospective evaluation of radical surgery for adenocarcinoma of oesophagogastric junction: real-world insights from the CLAEG study.
-
promotes gastric cancer metastasis via NA-mediated NAD metabolism reprogramming and glycolytic activation.
-
E-cadherin loss in Cd44-positive gastric cells initiates diffuse gastric cancer in a murine model.
-
Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy.
-
Integrative proteogenomics maps multifactorial aetiology, progression and therapeutic vulnerabilities in gastric cancer.
-
marks gastric corpus progenitors that give rise to pyloric metaplasia/SPEM following injury.
-
Gastric microbiota-mediated immune remodelling in gastric cancer.
-
CD48 is a novel immune checkpoint on tumour-associated macrophages in hepatocellular carcinoma.
-
Discovery of a carboxyl fullerene derivative as a new lipid droplet regulator inhibiting MASLD.
-
Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease.